Kiniksa Pharmaceuticals International, PLC

Biopharmaceutical company developing immune-modulating therapies, focused on cardiovascular diseases such as recurrent pericarditis

London, United KingdomFounded 2024kiniksa.com Website technologies

+ Add to sales board

Highlights

Young companyFounded 2024
New on EvolcAdded 2026-10-28

About Kiniksa Pharmaceuticals International, PLC

Kiniksa Pharmaceuticals is a biopharmaceutical company developing immune-modulating therapies, with a focus on cardiovascular diseases. Its FDA-approved product ARCALYST (rilonacept) is indicated for recurrent pericarditis. Its clinical-stage pipeline includes KPL-387, an investigational IL-1 receptor antagonist monoclonal antibody being tested in the pivotal Phase 3 PASTORALE trial in recurrent pericarditis.

The company develops therapies for patients with debilitating diseases and out-licenses and in-licenses assets with partners. These include a collaboration with Huadong Medicine for ARCALYST and mavrilimumab in the Asia Pacific region (excluding Japan) and a global license agreement with Roche and Genentech for vixarelimab.

The website dates the company's founding to 2015. The UK PLC entity was registered in London in 2024, and the company listed on the NASDAQ Global Market in 2018 after an IPO. Offices are in London, Lexington (Massachusetts, USA, listed as its USA headquarters), Zug (Switzerland) and La Jolla (California, USA).

Product: ARCALYST (rilonacept), an FDA-approved therapy for recurrent pericarditis, and investigational KPL-387 in Phase 3 development.

Jobs at Kiniksa Pharmaceuticals International, PLC

No open positions listed right now.

Leadership

Sanj K. Patel · CEO & Chairman of the Board
Source: company website
Mark Ragosa · Chief Financial Officer
Source: company website
Mei Jang · Chief Technical Officer
Source: company website
Ross Moat · Chief Operating Officer
Source: company website

More biotech & pharma companies

Kinomica
Phosphoproteomic diagnostic platform KScan for cancer treatment-response prediction, for clinicians and drug developers
Macclesfield, United KingdomBiotech & pharmaFounded 20162 open jobs
New on EvolcRemote-friendly
Kirkstall
Organ-on-a-chip flow cell culture systems for studying drug toxicity and disease in academic and pharma labs
Barnsley, United KingdomBiotech & pharmaFounded 20001 open job
New on Evolc
LabGenius
Machine-learning and automation platform for discovering therapeutic antibodies for biotechnology and pharmaceutical companies
United KingdomBiotech & pharma2 open jobs
New on EvolcRemote-friendly
Lario Therapeutics
Develops disease-modifying precision medicines for severe epileptic disorders and Parkinson's disease, starting
Edinburgh, United KingdomBiotech & pharmaFounded 2021
Young companyNew on Evolc
Levicept
Develops a non-opioid biologic treatment for osteoarthritis pain for patients with painful joint disease
Sandwich, United KingdomBiotech & pharmaFounded 2012
New on Evolc
LGC Group
Reference materials, diagnostic quality controls and analytical standards for labs and life-science companies
United KingdomBiotech & pharma107 open jobs
New on Evolc